Enovis (NYSE:ENOV) Given New $39.00 Price Target at Wells Fargo & Company

Enovis (NYSE:ENOV) had its target price lowered by research analysts at Wells Fargo & Company from $40.00 to $39.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 46.62% from the stock’s current price.

ENOV has been the subject of a number of other research reports. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday, July 6th. UBS Group reiterated a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Zacks Research raised Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. BMO Capital Markets restated an “outperform” rating and set a $30.00 target price on shares of Enovis in a research note on Friday. Finally, William Blair initiated coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating on the stock. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.00.

Enovis Stock Performance

ENOV stock traded up $0.29 during midday trading on Friday, hitting $26.60. 322,621 shares of the company traded hands, compared to its average volume of 1,094,209. Enovis has a twelve month low of $19.14 and a twelve month high of $34.28. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -1.33 and a beta of 1.34. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87. The business has a 50 day simple moving average of $24.54 and a 200-day simple moving average of $23.95.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. Enovis’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts predict that Enovis will post 3.12 earnings per share for the current year.

Insider Activity

In related news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have bought 4,200 shares of company stock worth $92,084. Insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

A number of institutional investors have recently added to or reduced their stakes in ENOV. AQR Capital Management LLC increased its stake in Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after acquiring an additional 7,072 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after purchasing an additional 73,116 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Finally, Amundi increased its position in shares of Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after purchasing an additional 9,762 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported second-quarter adjusted EPS of $0.90, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million also slightly exceeded estimates and increased 3.2% year over year. Enovis Second Quarter Earnings Results
• Positive Sentiment: Reconstructive sales were a key growth driver, rising 8% on a reported basis and 6% organically. Total second-quarter sales grew 3% reported and 5% organically, supporting the company’s long-term growth strategy. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, signaling continued analyst confidence in Enovis’ potential despite near-term execution concerns. BTIG Research Price Target Report
• Neutral Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue guidance of $2.3 billion to $2.4 billion and EPS guidance of $3.52 to $3.73. The EPS range brackets the roughly $3.54 consensus estimate, offering limited near-term guidance upside. Enovis 2026 Second Quarter Results Presentation
• Negative Sentiment: Investors reacted negatively to commentary characterizing quarterly performance as softer than expected. Although the company beat consensus estimates, the modest overall sales growth and lack of an upward guidance revision appear to have raised concerns about momentum and execution. Enovis Shares Drop After Second Quarter Earnings

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.